$1.78
3.26% yesterday
Nasdaq, Sep 03, 10:09 pm CET
ISIN
CA59935V1076
Symbol
MIST

Milestone Pharmaceuticals, Inc. Stock price

$1.78
+0.29 19.46% 1M
+0.13 7.88% 6M
-0.58 24.58% YTD
+0.39 28.06% 1Y
-6.89 79.47% 3Y
-5.93 76.91% 5Y
-13.22 88.13% 10Y
-13.22 88.13% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.06 3.26%
ISIN
CA59935V1076
Symbol
MIST
Industry

Key metrics

Basic
Market capitalization
$151.3m
Enterprise Value
$163.1m
Net debt
$11.8m
Cash
$43.4m
Shares outstanding
53.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
17.4%
Return on Equity
-315.8%
ROCE
-144.3%
ROIC
-
Debt/Equity
-3.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-54.9m | $-20.4m
EBIT
$-55.0m | $-66.6m
Net Income
$-55.5m | $-46.4m
Free Cash Flow
$-40.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-11.6% | 51.4%
EBIT
-11.6% | -58.2%
Net Income
-14.7% | -11.7%
Free Cash Flow
-9.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.8
Short interest
6.7%
Employees
33
Rev per Employee
$0.0
Show more

Is Milestone Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Milestone Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Milestone Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 38 38
25% 25%
-
- Research and Development Expense 17 17
11% 11%
-
-55 -55
12% 12%
-
- Depreciation and Amortization 0.11 0.11
0% 0%
-
EBIT (Operating Income) EBIT -55 -55
12% 12%
-
Net Profit -56 -56
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Milestone Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Milestone Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
16 days ago
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C.
Neutral
GlobeNewsWire
23 days ago
FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025
Positive
Seeking Alpha
about 2 months ago
Despite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and dilutive, but it ensures Milestone's survival even if approval is delayed. Our updated financial model reflects higher risk, dilution, and a later launch, reducing risk-adjusted fair value but sti...
More Milestone Pharmaceuticals, Inc. News

Company Profile

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Head office Canada
CEO Joseph Oliveto
Employees 33
Founded 2003
Website www.milestonepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today